M&A / Deals Eli Lilly makes $7.8bn takeover play for Centessa PharmaphorumSleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.M&A / DealsRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) Pharmaphorum Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Merck strikes deal with antibody discovery startupNext: Biogen swoops on Apellis with $5.6bn offer Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
